by The global continuous renal replacement therapy market size accounted for USD 1.46 billion in 2023 and is projected to hit around USD 3 billion by 2032, registering a CAGR of 8.60% during the forecast period from 2023 to 2032.
Key Takeaways
- North America contributed more than 36% of revenue share in 2022.
- Asia-Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
- By product, the consumables segment has held the largest market share of 60% in 2022.
- By product, the system segment is anticipated to grow at a remarkable CAGR of 9.1% between 2023 and 2032.
- By modality, the continuous venovenous hemofiltration (CVVH) segment generated over 32% of revenue share in 2022.
- By modality, the continuous venovenous hemodiafiltration (CVVHDF) segment is expected to expand at the fastest CAGR over the projected period.
The continuous renal replacement therapy market report offers an exclusive study of the present state expected at the market dynamics, opportunities, market scheme, growth analysis and regional outlook. The report presents energetic visions to conclude and study the market size, market aspiration, and competitive environment. The research also focuses on the important achievements of the market, research & development, and regional (country by country) growth of the leading vendors operating in the market
The study offers intricate dynamics about different aspects of the global continuous renal replacement therapy market, which aids companies operating in the market in making strategies development decisions. The study also elaborates on remarkable changes that are highly anticipated to configure growth of the global continuous renal replacement therapy market during the forecast period. It also includes a key indicator analysis that highlights growth prospects of this market and approximate statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).
Sample Link @ https://www.precedenceresearch.com/sample/3613
Continuous Renal Replacement Therapy Market Scope
| Report Coverage | Details |
| Growth Rate from 2023 to 2032 | CAGR of 8.60% |
| Market Size in 2023 | USD 1.46 Billion |
| Market Size by 2032 | USD 3 Billion |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product and By Modality |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
This study covers an elaborate segmentation of the global continuous renal replacement therapy market, along with important information and a competition outlook. The report mentions company profiles of players that are currently influence the global continuous renal replacement therapy market, wherein various developments, expansions, and winning strategies practiced and execute by leading players have been presented in detail.
Read Also: Biopsy Devices Market Size To Attain USD 4.29 Billion By 2032
Continuous Renal Replacement Therapy Market Players
- Baxter International Inc.
- Fresenius Medical Care AG & Co. KGaA
- B. Braun Melsungen AG
- NxStage Medical, Inc. (a subsidiary of Fresenius Medical Care)
- Nikkiso Co., Ltd.
- Asahi Kasei Corporation
- Infomed SA
- Toray Medical Co., Ltd.
- Medtronic plc
- Medica S.p.A.
- Biolight Co., Ltd.
- SWS Hemodialysis Care Co., Ltd.
- Nipro Corporation
- Bellco S.r.l.
- Asahi Biomed Co., Ltd.
Segments Covered in the Report
By Product
- System
- Consumables
By Modality
- Slow Continuous Ultra-Filtration (SCUF)
- Continuous Venovenous Hemofiltration (CVVH)
- Continuous Venovenous Hemodialysis (CVVHD)
- Continuous Venovenous Hemodiafiltration (CVVHDF)
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Research Methodology
The research methodology acquire by analysts for assemble the global continuous renal replacement therapy market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts study numerous annual report declaration, white papers, market association declaration, and company websites to obtain the necessary understanding of the global continuous renal replacement therapy market.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Continuous Renal Replacement Therapy Market
5.1. COVID-19 Landscape: Continuous Renal Replacement Therapy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Continuous Renal Replacement Therapy Market, By Product
8.1. Continuous Renal Replacement Therapy Market, by Product, 2023-2032
8.1.1. System
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Continuous Renal Replacement Therapy Market, By Modality
9.1. Continuous Renal Replacement Therapy Market, by Modality, 2023-2032
9.1.1. Slow Continuous Ultra-Filtration (SCUF)
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Continuous Venovenous Hemofiltration (CVVH)
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Continuous Venovenous Hemodialysis (CVVHD)
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Continuous Venovenous Hemodiafiltration (CVVHDF)
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Continuous Renal Replacement Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Product (2020-2032)
10.1.2. Market Revenue and Forecast, by Modality (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Product (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Modality (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Product (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Modality (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Product (2020-2032)
10.2.2. Market Revenue and Forecast, by Modality (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Product (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Modality (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Product (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Modality (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Modality (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Modality (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Product (2020-2032)
10.3.2. Market Revenue and Forecast, by Modality (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Product (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Modality (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Product (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Modality (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Modality (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Modality (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Product (2020-2032)
10.4.2. Market Revenue and Forecast, by Modality (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Product (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Modality (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Product (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Modality (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Modality (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Modality (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Product (2020-2032)
10.5.2. Market Revenue and Forecast, by Modality (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Product (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Modality (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Product (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Modality (2020-2032)
Chapter 11. Company Profiles
11.1. Baxter International Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Fresenius Medical Care AG & Co. KGaA
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. B. Braun Melsungen AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. NxStage Medical, Inc. (a subsidiary of Fresenius Medical Care)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Nikkiso Co., Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Asahi Kasei Corporation
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Infomed SA
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Toray Medical Co., Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Medtronic plc
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Medica S.p.A.
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
